Results 101 to 110 of about 11,769,643 (158)

Advancing Next-Generation Psychedelic Therapeutics through Selective 5‑HT2A Activation, Precision Aerosol Delivery, and Optimized 5‑MeO-DMT Treatment Paradigms. [PDF]

ACS Med Chem Lett
Renner AC, Kargbo RB.
europepmc   +1 more source

Sleep-like state during wakefulness induced by psychedelic 5-MeO-DMT in mice

, 2022
Bréant BJB, Mengual JP, Hoerder-Suabedissen A, Patel J, Bannerman DM, Sharp T, Vyazovskiy VV.   +6 more
europepmc   +1 more source

Novel Thermosensitive and Mucoadhesive Nasal Hydrogel Containing 5-MeO-DMT Optimized Using Box-Behnken Experimental Design. [PDF]

Polymers (Basel)
Miranda P, Castro A, Díaz P, Minini L, Ferraro F, Paulsen E, Faccio R, Pardo H.   +7 more
europepmc   +1 more source

Editorial: Beyond psilocybin: exploring the clinical potential of alternative and novel psychedelics

Frontiers in Psychiatry
Martin L. Williams, Martin L. Williams, Deborah Rudin, Deborah Rudin, Yasmin Schmid, Yasmin Schmid, Jacqueline von Salm   +6 more
doaj   +1 more source

Editorial: Down the rabbit hole – the psychological and neural mechanisms of psychedelic compounds and their use in treating mental health and medical conditions

Frontiers in Psychiatry
Leehe Peled-Avron, Leehe Peled-Avron, Leehe Peled-Avron, Jacob S. Aday, Amilia Lydia Kalafateli, Holly K. Hamilton, Holly K. Hamilton, Joshua D. Woolley, Joshua D. Woolley   +8 more
doaj   +1 more source

A systematic review of the pharmacokinetics of classical serotonergic psychedelic compounds in healthy adult subjects. [PDF]

J Psychopharmacol
Hampsey E, Martin K, Kalfas M, Benson L, Wihlborg S, Jelen L, Young AH, Rucker J.   +7 more
europepmc   +1 more source

Short- and Long-Acting Psychedelics: Structure-Activity Relationships, Pharmacology, and Implications for Neuropsychiatric Therapeutics. [PDF]

ACS Chem Neurosci
Bhat A, Zolali E, Sakib MA, Rahimian M, McMahon LR, German N, Obeng S.   +6 more
europepmc   +1 more source

Serotonin Transporter Blockade Reduces the Psychedelic-Like Effects of 4-Methoxy-<i>N</i>-methyl-<i>N</i>-isopropyltryptamine and Related Analogs. [PDF]

ACS Chem Neurosci
Glatfelter GC, Schalk SS, Walther D, Maitland AD, Gonzalez NR, Partilla JS, Anas NA, Chadeayne AR, Naeem M, Manke DR, McCorvy JD, Baumann MH.   +11 more
europepmc   +1 more source

Overcoming Pharmacokinetic and Peripheral Safety Challenges in Psychedelic Therapies: The Promise of Advanced Drug Delivery Systems. [PDF]

ACS Pharmacol Transl Sci
Zhang T, Lin C, Wang X.
europepmc   +1 more source